Gene profiling should be offered to some patients with breast cancer, says NICE

Patients with a type of early breast cancer who are at risk of it spreading should be offered gene expression profiling to help personalise treatment decisions, the National Institute for Health and Care Excellence (NICE) has said.1

The updated NICE quality standard says that people with oestrogen receptor positive (ER positive), human epidermal growth factor receptor 2 negative (HER2 negative), or lymph node negative early breast cancer who are at intermediate risk of distant recurrence should be offered the Oncotype DX test. The test provides information about the genetic make-up of the …